New Migraine Prevention Trial Enters Final Study Phase
Adults living with migraines are being studied to see if this treatment could potentially reduce monthly symptom days.
Updated on Oct. 15, 2026 in Alzheimer’s
Live Poll
Do you feel new medical treatment options are becoming available fast enough in your country?
Merz Therapeutics has finished recruiting 1,800 participants for two Phase III clinical trials, MINT-E and MINT-C, to study XEOMIN for migraine prevention. These trials, conducted across 109 sites in North America and Europe, aim to determine the drug's effectiveness for adults living with chronic or episodic migraines.
Why it matters
With approximately 1.1 billion people affected by migraine worldwide, there is a constant need to expand the pipeline of preventive treatment options. These trials represent a critical step toward potentially adding a new, globally available therapy to the current standard of care for migraine management.
These Phase III trials involve 1,800 adults across 109 study sites in North America and Europe to evaluate the use of XEOMIN for migraine prevention. The researchers are measuring the change in monthly migraine days from baseline to Month 6, though final results are not yet known.
The players
Merz Therapeutics
A division of the Merz Group, a German-based company with a 117-year history that develops pharmaceuticals for neurotoxin therapy and aesthetics.
The details
The MINT-E and MINT-C trials assess whether XEOMIN can reduce the frequency of both episodic and chronic migraines. Researchers are primarily tracking the change in monthly migraine days, with secondary endpoints including monthly headache days, the number of acute medication days used by participants, and overall migraine frequency. While XEOMIN is approved for other indications in over 80 countries, it is not yet approved for migraine prevention.
Timeline
October 15, 2026: Merz Therapeutics announced the completion of patient recruitment.
2027: The main study period is expected to conclude.
Health Landscape
This development follows the established pattern of large-scale Phase III trials aimed at expanding the therapeutic indications for existing neurotoxin-based products. It contributes to the broader global effort to address the massive burden of migraine by testing new preventive applications.
While these findings are early, adults living with chronic or episodic migraine may want to discuss the current landscape of preventive options with their physician. Note that XEOMIN is not yet approved for this purpose, and its potential role in your personal care plan depends on future trial results.
The takeaway
Large-scale clinical trials are currently underway to determine if XEOMIN can serve as a new preventive measure for migraine sufferers. If you manage chronic or episodic migraines, consult your doctor to stay updated on emerging evidence and approved preventive therapies.
Further reading
For more on managing chronic neurological conditions, visit our Alzheimer’s section.
Live Poll
Do you feel new medical treatment options are becoming available fast enough in your country?
